14:08 , May 18, 2018 |  BC Week In Review  |  Financial News

Imprimis spinout Surface raises $20M series A

Eye disease company Surface Pharmaceuticals Inc. (Pleasanton, Calif.) launched with a $20 million series A round funded by an investment entity managed by Flying L Partners. Surface is a spinout from drug delivery company and...
22:34 , May 15, 2018 |  BC Extra  |  Financial News

Imprimis spinout Surface raises $20M series A

Eye disease company Surface Pharmaceuticals Inc. (Pleasanton, Calif.) launched with a $20 million series A round funded by an investment entity managed by Flying L Partners. Surface is a spinout from drug delivery company and...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

Enstilar calcipotriene/betamethasone dipropionate aerosol foam regulatory update

The U.K. approved Leo’s Enstilar calcipotriene/ betamethasone foam spray to treat plaque psoriasis in adults. In March, Leo said Enstilar received a positive outcome under EU’s decentralized procedure (see BioCentury, April 11). The aerosol foam...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Enstilar calcipotriene/betamethasone dipropionate aerosol foam regulatory update

Leo said Enstilar calcipotriene/betamethasone received a positive outcome under EU’s decentralized procedure to treat plaque psoriasis in adults. Leo expects national approvals this year. The aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene,...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Marduox maxacalcitol/betamethasone butyrate propionate regulatory update

Japan approved an NDA from Chugai for Marduox maxacalcitol/betamethasone butyrate propionate to treat psoriasis vulgaris. The product is a topical combination of Oxarol maxacalcitol, an active vitamin D3 derivative from Chugai, and betamethasone butyrate propionate,...
07:00 , Apr 4, 2016 |  BioCentury  |  Regulation

Looking beyond appearances

Psoriasis patients have told FDA they need relief from more symptoms than the visible skin lesions that often serve as the primary endpoint of registrational trials. The need is not lost on drug developers, which...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Calcipotriene/betamethasone dipropionate aerosol foam regulatory update

FDA approved Enstilar calcipotriene/betamethasone to treat plaque psoriasis in patients ages >=18 years. Leo plans to launch the aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene, a synthetic vitamin D3 analog, and 0.064%...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Calcipotriene/betamethasone dipropionate aerosol foam: Phase III data

The double-blind, placebo-controlled, U.S. Phase III PSO-FAST trial in 426 patients with psoriasis vulgaris showed that Enstilar improved itch in 37% of patients after 3 days and in 84% of patients by week 4. Additionally,...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Maxacalcitol/betamethasone butyrate propionate regulatory update

Chugai submitted an NDA in Japan for M8010 to treat psoriasis vulgaris. M8010 is a topical combination of Oxarol maxacalcitol, an active vitamin D3 derivative from Chugai, and betamethasone butyrate propionate, a corticosteroid. Both compounds...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

Can-Fite, Cipher deal

Can-Fite granted Cipher rights to commercialize Can-Fite’s CF101 in Canada to treat moderate to severe psoriasis and rheumatoid arthritis. The adenosine A3 receptor (ADORA3) agonist has completed a Phase II/III trial to treat...